SCI Pharmtech, Inc. (TPE:4119)
Taiwan · Delayed Price · Currency is TWD 53.80
-0.80 (-1.47%)
Sep 8, 2026, 1:30 PM CST
SCI Pharmtech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,430 | 5,820 | 10,827 | 11,568 | 9,300 | 8,012 | |
Market Cap Growth | -11.07% | -46.25% | -6.40% | 24.39% | 16.07% | 20.00% |
Enterprise Value | 7,406 | 6,694 | 11,388 | 12,218 | 9,171 | 6,991 |
Last Close Price | 53.80 | 47.88 | 87.02 | 91.69 | 80.64 | 69.47 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 107.51 | 54.20 | 20.25 | 39.25 | 30.12 | 143.85 |
Forward PE | - | 47.26 | 29.34 | 29.34 | 39.47 | 89.36 |
PS Ratio | 5.10 | 4.33 | 7.11 | 9.61 | 10.34 | 9.27 |
PB Ratio | 1.21 | 1.08 | 1.98 | 2.27 | 2.56 | 2.41 |
P/TBV Ratio | 1.22 | 1.09 | 1.99 | 2.29 | 2.60 | 2.46 |
P/OCF Ratio | 28.72 | 26.42 | 12.58 | 53.62 | 31.36 | 28.59 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.88 | 4.98 | 7.47 | 10.15 | 10.19 | 8.09 |
EV/EBITDA Ratio | 24.56 | 16.63 | 26.50 | 40.23 | 44.10 | 51.56 |
EV/EBIT Ratio | 162.60 | 43.12 | 57.43 | 76.22 | 77.09 | 94.91 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.20 | 0.18 | 0.18 | 0.20 | 0.15 | 0.00 |
Debt / EBITDA Ratio | 2.95 | 2.42 | 2.29 | 3.41 | 2.60 | 0.02 |
Net Debt / Equity Ratio | 0.18 | 0.17 | 0.05 | 0.00 | 0.08 | -0.21 |
Net Debt / EBITDA Ratio | 2.77 | 2.27 | 0.69 | 0.04 | 1.35 | -5.09 |
Net Debt / FCF Ratio | -5.60 | -2.34 | -3.46 | -0.01 | -0.32 | 1.41 |
Asset Turnover | 0.18 | 0.19 | 0.22 | 0.21 | 0.20 | 0.20 |
Inventory Turnover | 1.43 | 1.47 | 1.94 | 1.64 | 1.51 | 1.94 |
Quick Ratio | 0.33 | 0.31 | 0.97 | 2.35 | 0.61 | 1.39 |
Current Ratio | 1.25 | 1.05 | 1.64 | 3.43 | 1.35 | 1.87 |
Return on Equity (ROE) | 1.12% | 1.98% | 10.11% | 6.75% | 8.89% | 1.68% |
Return on Assets (ROA) | 0.93% | 1.38% | 1.78% | 1.72% | 1.63% | 1.05% |
Return on Invested Capital (ROIC) | 1.29% | 2.57% | 3.01% | 2.88% | 2.90% | 2.35% |
Return on Capital Employed (ROCE) | 1.70% | 2.70% | 3.20% | 2.60% | 2.80% | 2.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.94% | 1.85% | 4.94% | 2.55% | 3.32% | 0.69% |
FCF Yield | -2.71% | -6.69% | -0.80% | -7.03% | -9.37% | -6.13% |
Dividend Yield | 1.34% | 1.57% | 1.72% | 1.36% | 0.28% | - |
Payout Ratio | 298.19% | 166.95% | 27.94% | 8.09% | - | 71.36% |
Buyback Yield / Dilution | 0.17% | 0.13% | -9.44% | -1.87% | -0.08% | 0.49% |
Total Shareholder Return | 1.51% | 1.70% | -7.71% | -0.51% | 0.20% | 0.49% |